arginine-butyrate has been researched along with Sarcoma-180* in 3 studies
3 other study(ies) available for arginine-butyrate and Sarcoma-180
Article | Year |
---|---|
Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.
The analysis of the likely physiological role of interferon during pregnancy and antitumor protection can be employed in developing a new strategy in antitumor therapy. Indeed, pretreatment of the patients with a potent immune stimulation compensates to some extent interferon's immune repressive effects. Through the modulation of the cytoskeleton, interferon enhances macrophage activity. Moreover, butyrate by its own effect on the malignant phenotype increases interferon sensitivity in a number of malignant cells. All of these substances should be used at the lowest possible concentration delivered as closely as possible to the target area. Topics: Amniotic Fluid; Animals; Arginine; Butyrates; Cytoskeleton; Extracellular Matrix; Female; Humans; Immune System; Interferons; Mice; Mice, Inbred AKR; Neoplasms; Pregnancy; Propionibacterium acnes; Rats; Sarcoma 180 | 1984 |
Antitumor effect of arginine butyrate in conjunction with Corynebacterium parvum and interferon.
The antitumor effect of arginine butyrate, used alone or in conjunction with interferon (IFN), was studied using randomly selected Swiss mice inoculated i.p. with 10(6) 180 TG Crocker tumor cells. The results of these different therapeutic regimens were estimated by tumor incidence at 10 days, by the time necessary to protect 50% of the animals, and by the final survival rate. Combined treatment by IFN and arginine butyrate was effective; but in order to compensate for IFN's immune repressive effects, a single injection of Corynebacterium parvum was administered in some experiments prior to IFN and/or arginine butyrate. After this immune potentiation, both IFN and arginine butyrate used separately significantly protected the animals. However, optimal results were obtained when a single C. parvum injection was followed by nine daily alternating shots of arginine butyrate and IFN. Topics: Animals; Arginine; Butyrates; Carcinoma, Ehrlich Tumor; Immunotherapy; Interferons; Male; Mice; Propionibacterium acnes; Sarcoma 180 | 1982 |
[Inhibitory effect of arginine butyrate on the development of Crocker 180/TG tumor in Swiss mice].
Arginine butyrate slightly increases the resistance of Swiss Mice to allografted 180/TG tumor cells. A single injection of Corynebacterium Parvum has comparable effects. However, it they are associated, survival rate is significantly augmented. Topics: Animals; Antineoplastic Agents; Arginine; Bacterial Vaccines; Butyrates; Male; Mice; Propionibacterium acnes; Sarcoma 180 | 1981 |